Ionis Pharmaceuticals (IONS) Change in Accured Expenses (2013 - 2026)

Ionis Pharmaceuticals' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $14.2 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 28.74% year-over-year to $14.2 million; the TTM figure through Jun 2026 stood at $3.7 million (up 113.89% YoY), while the FY2025 annual figure was $46.6 million, up 208.44% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at $14.2 million, up from -$80.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $110.7 million in Q3 2025, with the low at -$80.2 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $222500.0 (2023), against an average of $162777.8.
• Peak annual rise in Change in Accured Expenses reached 6933.89% in 2022, while the deepest fall reached 429.22% in 2022.
• Ionis Pharmaceuticals' Change in Accured Expenses stood at $8.4 million in 2022, then soared by 407.21% to $42.8 million in 2023, then sank by 133.51% to -$14.3 million in 2024, then tumbled by 186.5% to -$41.1 million in 2025, then soared by 134.69% to $14.2 million in 2026.
• Business Quant data shows IONS's Change in Accured Expenses at $14.2 million in Q2 2026, -$80.2 million in Q1 2026, and -$41.1 million in Q4 2025.